Phase III REGENCY trial
Roche’s Gazyva Shows Promising Results in Phase III Lupus Nephritis Trial
Gazyva, obinutuzumab, lupus nephritis, Phase III REGENCY trial, complete renal response, Roche, autoimmune disease, kidney function
Actionable Insights Powered by AI
Gazyva, obinutuzumab, lupus nephritis, Phase III REGENCY trial, complete renal response, Roche, autoimmune disease, kidney function